Stockwatch. Combined harvesting
This article was originally published in Scrip
One can wait a long time to see strategic thinking in life science sector so it is unusual (and pleasing) when two examples emerge in a single week.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.